Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Amicus Therapeutics, Inc.

Amicus Therapeutics is a biotechnology company focused on developing therapies for rare diseases. It specializes in advanced therapies for various genetic conditions, as self-described.

Metric
Company Name	Amicus Therapeutics, Inc.
Symbol	FOLD
MSH ID	COM:AMICUSRX
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	517
Website	amicusrx.com
LinkedIn
Founders

Metric
Market Cap	3.06B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	399.36M
Revenue (LTM)
Revenue (NTM)
Gross Profit	354.16M
EBITDA	-65.62M
Operating Income	-73.49M
Net Income	-151.58M
EPS	-0.51
Diluted EPS	-0.51
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.90
Operating Profit Margin	-0.06
EBITDA Margin	-0.16
Net Profit Margin	-0.26
Return on Equity	-0.86
Return on Assets	-0.16
Return on Capital Employed	-0.05

COM:AMICUSRX

Amicus Therapeutics

Last Close

9.50

22/11 21:00

Market Cap

3.06B

Beta: -

Volume Today

1.93M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-21.61
P/B Ratio	28.16
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	8.50
EV Multiple	-27.49

Metric
Days Sales Outstanding	71.88
Days Payables Outstanding	238.83
Days Inventory Outstanding	564.12
Operating Cycle	632.35
Cash Conversion Cycle	491.91
Asset Turnover	0.61

Metric
Operating Cash Flow	-69.09M
Free Cash Flow	-76.53M
Cash Flow to Debt	-0.11
Operating Cash Flow/Sales	-0.09
Free Cash Flow Yield	-0.04

Metric
Cash & Equivalents	246.99M
Accounts Receivable	-20.11M
Inventory	59.70M
Goodwill	197.80M
Debt to Capitalization	0.75
Debt to Assets	0.59
Current Ratio	2.73
Quick Ratio	2.61

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.19
R&D to Revenue	0.49
SG&A to Revenue